Friday, May 17 2013 9:05 PM EDT2013-05-18 01:05:04 GMT
The Southwest Louisiana Tea Party movement began picking up steam in 2009 as members from throughout the five parish area began gathering for rallies and becoming more visible and involved in local governmentMore >>
The Southwest Louisiana Tea Party movement began picking up steam in 2009 as members from throughout the five-parish area began gathering for rallies and becoming more visible and involved in local government and the political scene.More >>
Friday, May 17 2013 8:55 PM EDT2013-05-18 00:55:58 GMT
An arrest has been made in the 1962 death of Mary Horton Vail. Vail was found dead in the Calcasieu River in October 1962, her husband, Felix Vail, claimed she was the victim of a boating accident. TheMore >>
Mary Horton Vail was found dead in the Calcasieu River in October 1962. Her husband, Felix Vail, claimed she was the victim of a boating accident.More >>
Friday, May 17 2013 6:17 PM EDT2013-05-17 22:17:04 GMT
Friday marks the anniversary of the first woman reported missing in the Jeff Davis Eight case. On May 17, 2005, 28-year-old Loretta Chaisson Lewis went missing. Three days later, her body was found floatingMore >>
Friday marks the anniversary of the first woman reported missing in the Jeff Davis Eight case.More >>
Friday, May 17 2013 5:47 PM EDT2013-05-17 21:47:38 GMT
More than 825 students - the largest graduating class in McNeese State University history - are expected to receive degrees at the university's spring commencement ceremony at 10 a.m. Saturday, May 18,More >>
More than 825 students - the largest graduating class in McNeese State University history - are expected to receive degrees at the university's spring commencement ceremony at 10 a.m. Saturday at Burton Coliseum.More >>
Friday, May 17 2013 5:44 PM EDT2013-05-17 21:44:31 GMT
In an area prone to hurricanes, flood insurance is important for Louisiana residents. Calcasieu Parish became a part of the National Flood Insurance program in 1978. By participating in the program,More >>
As a way to continue offering flood insurance, Congress passed the Biggert Waters Act in 2012. More >>
Local News, Weather, Traffic, Sports, Stocks, Movies on your Cell PhoneMore >>
Get local news, weather, sports, and video on your mobile device.More >>
Information contained on this page is provided by companies via press release distributed through PR Newswire, an independent third-party content provider. PR Newswire, WorldNow and this Station make no warranties or representations in connection therewith.
NEW YORK, Feb. 18, 2013 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Enterovirus-71 (EV-71), a small member of the picornaviridae virus family, is a major causative agent of "hand foot and mouth" HFMD disease in South East Asia. In some countries EV-71 related HFMD outbreaks appear to be increasing in magnitude and frequency and are responsible for significant childhood mortality (905 deaths in China2010) (est CFR 0.03%). Like Japanese encephalitis (JEV), an inactivated EV-71 vaccine has high likelihood of region specific national adoption in the SE Asia. Four such vaccines appear to be in late stage clinical trials in China with the first launch expected 2014.
This MarketVIEW product is a comprehensive commercial opportunity assessment which forecasts the potential of EV-71 vaccines to 2030 in the SE Asia region. The product examines different scenarios of sucessive country based vaccine deployment in the
<1 yrs and 1-5 yrs age groups. Detailed coverage of latest EV-71 epidemiology (outbreaks) is included, also a focus on development history/approaches to date and coverage of latest cost effectiveness issues. Expected revenues per competitor (public) sector are included for the late stage Phase III programs operated by Sinovac and China National Biotech Group (Beijing Vigoo Biological Co Ltd). >This product is an ideal starting point for any manufacturer wishing to assess this emerging market in the SE Asia region.
THIS PRODUCT IS A EXECUTIVE PRESENTATION + 2 MODELS Contents – Executive presentation (MS PowerPoint based)Author's noteExecutive summaryCommercial model – key outputsEV-71 vaccine(s): scenario definitionsTotal available global market to 2030: EV-71 vaccine(s)EV-71 vaccine: available market (0-5 yrs) to 2030EV-71 vaccine: total predicted volume (0-5 yrs) to 2030EV-71 vaccine: available market (<1 yrs) to 2030>EV-71 vaccine: available market (1-5 yrs) to 2030EV-71 vaccine: China market to 2030 (0-5 yrs) to 2030Total available global market to 2030: EV-71 vaccine(s) (public/private)SE Asia: cumulative first 5 year spend (public)Revenues per competitor to 2030: EV-71 vaccine(s) 0-5 yrs (CHINA)EV-71: epidemiology overviewEV-71: the pathogenComparing endemic diseasesEV-71: timelineEpidemiology: latest outbreaks in AsiaEpidemiology: incidence rates by countryEpidemiology: ChinaHFMD incidence rate, by province, January-May 2011, ChinaHFMD incidence rate, by province, January-May 9, 2008, ChinaDistribution of HFMD cases by province, January-May 2011, ChinaDistribution of severe HFMD cases (A) and deaths (B) by province, January-May 2011, ChinaEpidemiology: TaiwanEpidemiology: ThailandEpidemiology: VietnamEpidemiology: MalaysiaEpidemiology: South KoreaEpidemiology: JapanHFMD annual and weekly cases, sentinel-reports, JapanPercentage of HFMD cases by age group, sentinel-reports, 2000-2011Virus isolation/detection from aseptic meningitis cases, 2008-2012, JapanEpidemiology: SingaporeEpidemiology: USEpidemiology: EuropeEpidemiology: OtherEV-71: mortalityEV-71: morbidityEV-71 vaccine: modeling commercial potentialEV-71 vaccine opportunity: ideal target product profileModeling strategy: country/region inclusionEV-71 vaccine commercial model: countries included/scenariosModeling strategy: target populations (endemic)EV-71 vaccine: estimated order of vaccine use in target age groupsModeling strategy: launch sequence/roll-out (endemic)SE Asian countries: estimated launch dates per segmentOther countries: estimated launch dates per segmentEV-71: vaccine stockpile in Western countries?EV-71: vaccine: cost effectiveness analysisEV-71: prices used in modelEV-71: vaccinology, summary of competitor programsEV-71: vaccine: immunological aspectsEV-71: summary of vaccine approaches to dateEV-71: vaccine: need for cross protectionEvidence for the possibility of single genotype vaccine for EV-71Evidence against the possibility of single genotype vaccine for EV-71EV-71 vaccine: cross protection – other points to noteOther Coxsackieviruses and HFMDVaccine pipelineEstimating market share (CHINA)Opportunity for new treatmentsBibliographyDisclaimerAbout VacZine AnalyticsPAGES: ~90 MS PowerPoint slides, fully referenced/sourced. Available in .pdf formContents – Vaccine demand model(s) (MS Excel-based)Note: two models are included with differing vaccine price scenariosTitle sheetNotesCHARTS – VALUECHARTS VAL VOLCHART – COMPCompetitors (0-5 yrs)Value summary (0-5 yrs)Volume summary (0-5 yrs)Global price summaryLO SCENARIOPublic + privateCountry 1 – <1 yrs + 1-5 yrs>Country 2 – <1 yrs + 1-5 yrs>Country 3 – <1 yrs + 1-5 yrs>etcBASE SCENARIOPublic + privateCountry 4 – <1 yrs + 1-5 yrs>Country 5 – <1 yrs + 1-5 yrs>HI SCENARIOPublic + privateCountry 4 – <1 yrs + 1-5 yrs>Country 5 – <1 yrs + 1-5 yrs>Populations =>>Birth cohortsEpidemiology =>>% pub/priv% Urban populationTotal populationsBack pageWorksheets = 35 per model